Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Recurrent Breast Carcinoma|Stage IV Breast Cancer
Interventions: DRUG: Eribulin Mesylate|OTHER: Laboratory Biomarker Analysis
Sponsor: University of Washington
Collaborators: National Cancer Institute (NCI)